Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyBlue Cross NC Tocilizumab Coverage Update | OpenPa…
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - North CarolinaPolicy N/A

    Tocilizumab (Actemra) and Tocilizumab Biosimilars coverage

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - North Carolina policy alerts

    Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical policy governing prior authorization and medical necessity criteria for tocilizumab (Actemra) and specified biosimilars for outpatient/inpatient use for BCBS North Carolina members.

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyTocilizumab (Actemra) and Tocilizumab Biosimilars coverage
    Policy CodePolicy N/A
    Change TypeMaterial revisions and biosimilar additions (2024–2026)
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of prior trials/intolerance or MedWatch for biosimilar adverse events and include medical records for higher-than-labeled dose requests.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    July 2026: For CRS, allowed proactive prescribing in anticipation of CAR-T therapy, adjusted maximum units to reflect four 800 mg doses, and extended approval duration to 180 days (max 4 doses).

    April 2026: For SSc-ILD, separated intolerance/hypersensitivity from FDA contraindication criteria; updated continuation criteria to differentiate diagnoses and redirect to initial criteria for indications except SSc-ILD.

    October 2025: Added HCPCS Q5156 for Avtozma and deleted miscellaneous J/C codes termed 9/30/2025.

    July 2025: Added biosimilar Avtozma (tocilizumab-anoh) as non-preferred with requirement to trial and fail Tyenne; added dosing, max units, and HCPCS references.

    June 2024: Added biosimilars Tyenne (Q5135) and Tofidence (Q5133) and updated naming of policy to include biosimilars.

    180 daysDuration of approval - CRS
    365 daysDuration of approval - other
    3,200Max units - CRS
    20,800Max units - other
    TyennePreferred biosimilar
    4Max 800 mg IV doses - CRS

    Coverage and Medical Necessity Criteria

    inv-01: Initial Therapy Criteria

    Covered when ALL of the following are met (criteria vary by indication as detailed below):

    General requirements: 1) Prescribed for an FDA‑approved indication listed in policy; 2) Prescriber is a specialist in the area of the patient's diagnosis or has consulted one; 3) Will not be used in combination with another biologic immunomodulator agent or Otezla; 4) No FDA‑labeled contraindications to the requested tocilizumab product; 5) Patient has been tested for latent tuberculosis when required by the prescribing information and treatment begun if positive; 6) Requested quantity does not exceed the maximum units allowed for the duration of approval; 7) Site‑of‑care criteria apply for inpatient or outpatient hospital administration.

    See indication‑specific nodes below for age, required prior trials, and documentation expectations.

    Rheumatoid Arthritis (RA) initial criteria: Patient has moderately to severely active RA AND is ≥18 years of age AND ONE of: (a) inadequate response to maximally tolerated methotrexate for ≥3 months; OR (b) inadequate response to another conventional agent used for RA for ≥3 months; OR (c) intolerance or hypersensitivity to a conventional agent; OR (d) FDA‑labeled contraindication to all listed conventional agents; OR (e) patient is currently established on an FDA‑approved biologic/systemic immunomodulator for RA with documented clinical benefit plus additional documentation if switching from preferred agents is requested.

    Medical record documentation required for prior trials, intolerance/contraindication, or clinical benefit (see policy).

    Giant Cell Arteritis (GCA) initial criteria: Diagnosis of GCA AND age ≥18 years AND ONE of: inadequate response to systemic corticosteroids for 7–10 days; OR intolerance/hypersensitivity to systemic corticosteroids; OR FDA‑labeled contraindication to all systemic corticosteroids; OR currently established on an FDA‑approved biologic/systemic immunomodulator for GCA with documented clinical benefit.

    Medical record documentation required.

    Polyarticular Juvenile Idiopathic Arthritis (PJIA) initial criteria: Diagnosis of moderately to severely active PJIA AND age ≥2 years AND ONE of: inadequate response to one conventional agent used for PJIA for ≥3 months; OR intolerance/hypersensitivity to one conventional agent; OR FDA‑labeled contraindication to all conventional agents; OR currently established on an FDA‑approved biologic/systemic immunomodulator for PJIA with documented clinical benefit.

    Medical record documentation required.

    Systemic Juvenile Idiopathic Arthritis (SJIA) initial criteria: Diagnosis of active SJIA AND age ≥2 years AND ONE of: inadequate response to at least one NSAID for ≥1 month; OR intolerance/hypersensitivity to NSAIDs; OR FDA‑labeled contraindication to all NSAIDs; OR inadequate response to another conventional agent for ≥3 months; OR intolerance/hypersensitivity to conventional agent; OR FDA‑labeled contraindication to all conventional agents; OR currently established on an FDA‑approved biologic/systemic immunomodulator for SJIA with documented clinical benefit.

    Medical record documentation required.

    Cytokine Release Syndrome (CRS) initial criteria: Diagnosis of severe or life‑threatening CRS AND age ≥2 years AND request is for intravenous administration AND patient has received or will receive CAR T cell therapy AND ONE of: CRS was induced by CAR T cell therapy OR agent prescribed proactively to be on‑hand prior to CAR T cell therapy.

    Documentation of CAR T cell therapy and whether CRS is present or the agent is being prescribed proactively is required.

    Systemic sclerosis‑associated interstitial lung disease (SSc‑ILD) initial criteria: Diagnosis of SSc‑ILD AND age ≥18 years AND ALL of: disease onset (first non‑Raynaud symptom) ≤5 years; presence of elevated laboratory inflammatory markers (e.g., CRP, ESR, platelet count); active disease defined by at least one specified clinical metric (e.g., mRSS change, new body area involvement, tendon friction rub); ILD confirmed by chest high‑resolution CT; other known causes of ILD excluded; AND ONE of: inadequate response to one immunosuppressant therapy; OR intolerance/hypersensitivity to one immunosuppressant therapy; OR FDA‑labeled contraindication to all immunosuppressant therapy; OR currently established on a biologic/systemic immunomodulator with documented clinical benefit.

    Specific active‑disease definitions and required HRCT confirmation are specified in the policy; medical record documentation required.

    Non‑preferred product (Actemra or non‑preferred biosimilar) initial criteria: If request is for Actemra or a non‑preferred tocilizumab biosimilar, ONE of: (a) trial and inadequate response to preferred biosimilar Tyenne (tocilizumab‑aazg); OR (b) intolerance, FDA‑labeled contraindication, or hypersensitivity to Tyenne that is not expected to occur with the requested agent; OR (c) documented serious adverse event to Tyenne requiring medical intervention that is not anticipated with the requested agent (prescriber must submit FDA MedWatch Adverse Event Reporting Form).

    Medical record documentation and FDA MedWatch submission (when applicable) required.

    inv-02: Continuation Therapy

    Continuation therapy covered when criteria below are met:

    Continuation eligibility: Patient was approved through Blue Cross NC initial criteria OR the patient would have met initial criteria at the time therapy was started; for SSc‑ILD additional specific continuation allowances apply per policy; otherwise continuation follows initial criteria.

    Medical record documentation required to demonstrate prior approval or that initial criteria would have been met.

    Clinical benefit for continuation: Patient has demonstrated positive clinical response while using the medication — e.g., improvement or maintained annual rate of decline in pulmonary function (FVC% predicted) for SSc‑ILD or other indication‑specific evidence of benefit.

    Documentation of clinical response required in the medical record.

    Biosimilar step therapy for continuation: Requests for Actemra or a non‑preferred tocilizumab biosimilar at continuation require ONE of: trial and inadequate response to preferred biosimilar Tyenne; OR intolerance/hypersensitivity/FDA‑labeled contraindication to Tyenne not expected with requested agent; OR documented serious adverse event to Tyenne with FDA MedWatch submission — same requirements as for initial therapy.

    inv-03: Continuation Criteria / Dosing by Indication

    Continuation criteria and dosing by indication per FDA label and product‑specific details

    CRS (patients ≥2 years) IV dosing: IV dosing: weight <30 kg — 12 mg/kg per infusion; weight ≥30 kg — 8 mg/kg per infusion; dosing interval at least 8 hours between consecutive doses; not to exceed 800 mg per infusion; maximum of up to 4 doses.max 4 doses

    Maximum units for CRS listed as 3,200 in product tables; proactive (on‑hand) prescribing prior to CAR T cell therapy is allowed per July 2026 update.

    Rheumatoid Arthritis (adult) SC/IV dosing: SC and IV dosing per FDA label: SC examples — 162 mg schedules (weight‑based frequency: <100 kg every 2 weeks up to once weekly based on response; ≥100 kg once weekly); IV examples — 4–8 mg/kg every 4 weeks based on response, not to exceed 800 mg per infusion.see product‑specific maximum units

    Different biosimilars have assigned HCPCS codes (see coding).

    Giant Cell Arteritis (adult) dosing:

    inv-03: Continuation Criteria / Dosing by Indication

    Site of Care Medical Necessity Criteria

    Inpatient administration: Injection or infusion may be given in an inpatient setting if above medical necessity criteria are met AND the inpatient admission is NOT for the sole purpose of administering the injection or infusion.
    Outpatient hospital administration: Injection or infusion may be given in an outpatient hospital setting if above medical necessity criteria are met AND ONE of: history of a severe adverse event to the medication (e.g., anaphylaxis, seizure, thromboembolism, MI, renal failure); OR conditions that increase risk for severe adverse event (e.g., unstable renal or cardiopulmonary disease, unstable vascular access); OR history of mild adverse events not managed by pre‑medication; OR inability to adhere to treatment schedule; OR new to therapy (initial injection/infusion or <3 months since start); OR re‑initiation of therapy per defined gaps; OR requirement to change product formulation.
    ref':'b0_5
    title':'inv-05: Site of Care Criteria' } ]}],

    inv-04: Quantity Limit Exceptions

    Quantity Limit Exception Criteria

    Titration allowance: Quantity requested may be approved for documented titration at initiation of therapy (authorization for up to a 90‑day titration period).
    Dose strength substitution: Requested quantity must be necessary because the prescribed dose cannot be achieved using a lesser quantity of a higher strength formulation.
    ref':'b0_4
    title':'inv-04: Quantity Limit Exceptions'
    note

    The requested tocilizumab product must not be used in combination with another biologic immunomodulator agent or apremilast (Otezla®). This combination prohibition applies to all initial and continuation requests and medical record documentation must support the absence of concomitant biologic or Otezla use.

    An inpatient admission that is solely for the purpose of administering the injection or infusion is not supported. Inpatient administration is allowable only when the medical necessity criteria are met and the admission is not for the sole purpose of drug administration; otherwise the Site of Care criteria require administration in an alternate setting (home infusion or physician office) or meeting one of the outpatient hospital exceptions.

    Requests that exceed the policy's maximum units allowed for the duration of approval or that do not meet Site of Care requirements for inpatient or outpatient hospital administration may be considered not medically necessary. Quantity Limit Exception rules apply and require documentation when a dose exceeds standard limits (see exception criteria).

    Requests that exceed labeled dosing without required prescriber documentation may be denied. If the requested quantity exceeds the maximum FDA‑labeled dose or the safest studied dose, the prescriber must submit supporting documentation (medical records or fax form) showing prior use, duration, and prior medication trials/failures. Additionally, requests for inpatient administration that are solely for infusion or injection may be considered not medically necessary under the Site of Care criteria.

    Billing and Coding References

    Referenced HCPCS codes for ActemraHCPCS
    J3262tocilizumab (Actemra) HCPCS (referenced)
    Referenced HCPCS codes for biosimilarsHCPCS
    Q5156tocilizumab-anoh (Avtozma) HCPCS
    Referenced HCPCS codes for biosimilars (additional context)HCPCS
    Q5135tocilizumab-aazg (Tyenne) HCPCS
    Q5133tocilizumab-bavi (Tofidence) HCPCS
    HCPCS and historical billing codesHCPCS
    Q5156HCPCS for Avtozma (tocilizumab-anoh) IV/SC
    Q5133HCPCS for Tofidence (tocilizumab-bavi) IV
    Q5135HCPCS for Tyenne (tocilizumab-aazg) IV/SC
    C9399Deleted/termed miscellaneous code historically used for Tyenne (deleted 9/30/2024/2025)
    J3490Deleted/termed miscellaneous code historically used for Tyenne (deleted 9/30/2024/2025)
    J3590Deleted/termed miscellaneous code historically used for Tyenne (deleted 9/30/2024/2025)
    Age thresholds by indication
    Rheumatoid arthritis (RA)Age ≥18 years
    Giant cell arteritis (GCA)Age ≥18 years
    Systemic sclerosis-associated ILD (SSc-ILD)Age ≥18 years
    Polyarticular juvenile idiopathic arthritis (PJIA)Age ≥2 years
    Systemic juvenile idiopathic arthritis (SJIA)Age ≥2 years
    Cytokine release syndrome (CRS) — IV onlyAge ≥2 years

    Provider Requirements, Authorization, and Documentation

    Prior Authorization

    Prior Authorization and Coding References

    Prior authorization required for tocilizumab products and biosimilars administered by a healthcare professional. See HCPCS coding and maximum units in the FDA label reference tables for each product; requests that do not meet medical necessity criteria may be denied.

    • Prior authorization required for Actemra (tocilizumab), Avtozma (tocilizumab-anoh), Tofidence (tocilizumab-bavi), and Tyenne (tocilizumab-aazg).
    • Refer to product-specific HCPCS listed in the FDA label reference tables (e.g., Q5135, Q5156, Q5133) for billing.
    Documentation Required

    Quantity Over Labeled Maximum

    If the requested quantity (dose) exceeds the FDA labeled maximum or the safest studied dose per the manufacturer's product insert, the prescriber must submit supporting documentation demonstrating medical necessity for the higher dose. Documentation may include medical records or a completed fax form showing duration of use at the higher dose and prior medication trials/ failures.

    Clinical Background and Context

    Tocilizumab is an interleukin‑6 (IL‑6) receptor antagonist with multiple FDA‑approved indications including adult rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis (systemic and polyarticular forms), CAR T cell therapy–associated cytokine release syndrome (CRS), and systemic sclerosis‑associated interstitial lung disease (SSc‑ILD). Both intravenous and subcutaneous formulations are addressed by this policy, and indication‑specific dosing, age thresholds, and administration route requirements (for example, IV only for CRS) are specified in the coverage criteria.

    Definitions and Condition Summaries

    CRS (Cytokine Release Syndrome)
    DefinitionSevere or life‑threatening inflammatory syndrome often associated with CAR T cell therapy
    Indication and formulationCRS is an FDA‑recognized indication for IV tocilizumab (patients ≥2 years)
    Policy implicationIV tocilizumab may be approved proactively to have on‑hand prior to CAR‑T therapy for treatment of CRS
    SSc-ILD (Systemic sclerosis-associated interstitial lung disease)
    DefinitionInterstitial lung disease associated with systemic sclerosis (SSc‑ILD)
    Key approval criteriaDisease onset ≤5 years; elevated inflammatory markers (eg, CRP, ESR, platelet count); active disease per policy‑defined metrics; ILD confirmed by chest HRCT; exclusion of other causes
    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyTocilizumab (Actemra) and Tocilizumab Biosimilars coverage
    Policy CodePolicy N/A
    Change TypeMaterial revisions and biosimilar additions (2024–2026)
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of prior trials/intolerance or MedWatch for biosimilar adverse events and include medical records for higher-than-labeled dose requests.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling and Coding ReferencesProvider Requirements, Authorization, and DocumentationClinical Background and ContextDefinitions and Condition Summaries

    Prescriber specialty, no combination biologics/Otezla, quantity limits, and site‑of‑care criteria continue to apply.

    SC: 162 mg once weekly (or every other week may be considered per label); IV: 6 mg/kg every 4 weeks not to exceed 600 mg per infusion, per product labeling for GCA.

    Follow FDA label and product‑specific HCPCS guidance.

    PJIA and SJIA (patients ≥2 years) dosing: Weight‑based SC and IV dosing per FDA label: PJIA SC — <30 kg: 162 mg every 3 weeks; ≥30 kg: 162 mg every 2 weeks; IV — administered every 4 weeks: <30 kg: 10 mg/kg; ≥30 kg: 8 mg/kg. SJIA SC — <30 kg: 162 mg every 2 weeks; ≥30 kg: 162 mg once weekly; IV — every 2 weeks: <30 kg: 12 mg/kg; ≥30 kg: 8 mg/kg.

    Follow FDA label dosing for pediatric indications.

    SSc‑ILD (patients ≥18 years) dosing: SC: 162 mg once weekly per FDA label; continuation criteria for SSc‑ILD are handled separately and were updated in April 2026 to separate intolerance/hypersensitivity from FDA contraindication criteria.

    Documentation of pulmonary function and clinical benefit required for continuation.

    referring_error_fix_notes»:»none»}``` (Note: The above JSON contains malformed elements due to an editing error.)}]}]},
    Maximum IV doses for CRS
    Maximum number of IV doses for CRSUp to 4 doses
    Per-infusion maximumNot to exceed 800 mg per infusion
    Dosing intervals and weight-based dosingInterval ≥8 hours between doses; weight <30 kg: 12 mg/kg; weight ≥30 kg: 8 mg/kg
    • Requests exceeding FDA labeled maximum will require prescriber-submitted documentation (medical records or fax form).
    • Quantity requested for titration may be authorized for up to a 90-day titration period if criteria are met.
    Denial Risk

    Site-of-Care Inpatient Denial Risk

    Requests for inpatient administration will be denied when the inpatient admission is solely for the purpose of administering the injection or infusion. Outpatient hospital administration is allowed only when medical necessity criteria are met and one of the listed site-of-care conditions is present (e.g., history of severe adverse event, increased risk conditions, inability to adhere to regimen, new to therapy, re-initiation, or change in formulation). Otherwise, administration should occur in a home infusion or physician office setting.

    • Inpatient administration not allowed if admission is solely to receive infusion/injection.
    • Outpatient hospital administration requires meeting one of the specified criteria (severe adverse event history, high-risk conditions, unsuccessful management of mild adverse events, inability to adhere, new to therapy/re-initiation, change in formulation).
    • If site-of-care criteria not met, administration must occur in home-based infusion or physician office setting.
    Documentation Required

    Documentation for Higher-than-Labeled Doses

    When requesting doses above the labeled maximum, prescribers must submit medical record documentation supporting the dosing rationale. Acceptable evidence includes records showing the length of time the higher dose has been used, what other medications and doses were tried and failed, or completion of the policy fax form reflecting this information. Lack of supporting documentation may result in denial.

    • Documentation must show dosing rationale and prior therapy history if dose > FDA labeled maximum.
    • Submitted documentation may be medical records or a completed fax form reflecting clinical justification and treatment history.
    Step Therapy

    Step Therapy Among Tocilizumab Products

    Step therapy applies across tocilizumab products: trial and inadequate response to the preferred biosimilar Tyenne (tocilizumab-aazg) is required before approval of non-preferred tocilizumab products (e.g., Actemra, Avtozma, Tofidence), unless an approved exception applies.

    • Step therapy requires trial and inadequate response to Tyenne (tocilizumab-aazg) prior to non-preferred tocilizumab agents.
    • Medical record documentation of the trial and inadequate response is required.
    Step Therapy

    Biosimilar Trial-and-Failure

    For non-preferred tocilizumab biosimilars (e.g., Avtozma/tocilizumab-anoh, Tofidence/tocilizumab-bavi, and Actemra when considered non-preferred), approval requires trial and failure of the preferred biosimilar Tyenne (tocilizumab-aazg) OR documented intolerance, FDA-labeled contraindication, or a serious adverse event to Tyenne that is not expected with the requested agent. If relying on a serious adverse event, the prescriber must submit a completed FDA MedWatch Adverse Event Reporting Form.

    • Acceptable exceptions to trial-and-failure: documented intolerance, contraindication, or serious adverse event to Tyenne (with MedWatch submission).
    • Medical record documentation required for the trial failure or exception; prescriber must submit FDA MedWatch form when a serious adverse event is the basis for exception.
    Age requirementPatient must be ≥18 years of age
    CRS
    CRS associated settingOccurs with CAR‑T therapy; IV route only per FDA labeling
    IV dosing limitsUp to 4 IV doses (interval ≥8 hrs), weight‑based dosing: <30 kg = 12 mg/kg; ≥30 kg = 8 mg/kg; do not exceed 800 mg per infusion
    Authorization duration and unitsPolicy updated to reflect max four 800 mg doses and duration aligned to CAR‑T authorization timeframe (180 days)
    Biosimilar status (preferred vs non-preferred)
    Preferred biosimilarTyenne (tocilizumab‑aazg) is designated as the preferred tocilizumab biosimilar in policy
    Non‑preferred biosimilarsAvtozma (tocilizumab‑anoh) and Tofidence (tocilizumab‑bavi) are designated non‑preferred in policy and have additional step/trial requirements
    Trial requirementRequests for non‑preferred tocilizumab products generally require trial and inadequate response to Tyenne or acceptable documentation of intolerance/contraindication/serious adverse event with MedWatch submission